



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 27<sup>th</sup> September 2023

#### PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr Dominic Sebastian	Consultant Intensivist and Deputy DMD for SAS

#### IN ATTENDANCE:

Mr W Price	Dermatology Specialist Pharmacist ELHT
Mr J Eatough	Lead Pharmacist for Digestive Diseases&Hepatitis C
Mr Brian Ho	Gastroenterology Specialist Registrar
Mr M Tattersall	Clinical Pharmacist for Anaesthetics & Critical Care ELHT
Dr Anna Macpherson	Consultant in Palliative Medicine ELHT
Mr Matthew Tattersall	Clinical Pharmacist for Anaesthetics and Critical Care

#### 2023/108: APOLOGIES:

Dr F Shah  
Dr Mahadevan

#### 2023/109: DECLARATION OF INTEREST:

SR requested a DOI was recorded for herself at each meeting for Lilly/Novo/AZ.

#### 2023/110: MINUTES OF JULY TEAM MEETING:

Accepted as accurate record.

**Action:** July minutes to be uploaded to ELMMB website

#### 2023/111: MATTERS ARISING:

##### 2021/101b/ 2023/09: ELMMB Membership

**ELMMB TOR:** LR presented an updated version of the Terms of Reference the group. The group membership has been updated and will require further representation across



Primary and Secondary Care. This was highlighted as a possible challenge. AB to write to divisional directorates requesting nominees as permanent members.

UA mentioned that a reference to LCFT be amended to LSCFT.

**ACTION:** ELMMB terms of reference accepted with minor alteration. Item closed.

**2023/81/Ivermectin:** JV reported on the continuing supply issues with Permethrin cream with a medicines supply notice in place that recommends the use of Ivermectin tablets as one of the treatments. Ivermectin can be sourced through community pharmacy but there is a lead time of 4-5 days and as it is an imported licensed product it is expensive – approximately £190 for 4 x 200mg tablets. JV has explored the option to source via IMOT, but this is not an option. LR asked if ELHT could increase their stock to accommodate an expected increase in the use of ivermectin by dermatology. This can be recharged to ICB when used for community patients.

**ACTION:** Item closed.

### 2023/112: Formulary Updates

- a. **Nephrotrans® 500mg gastro-resistant capsules** (sodium hydrogen carbonate) for the treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in patients with chronic renal impairment. Not approved for prescribing on the NHS in L&SC **BLACK Traffic Light**
- b. **Glucagon pre-filled pen Ogluo®** - for severe hypoglycaemia in adults, adolescents and children aged 2 years and over with diabetes mellitus. **GREEN restricted Traffic Light**
- c. **IQoro® device** – for the treatment of stroke related dysphagia. **RED Traffic Light**
- d. **IQoro® device** - for the treatment of hiatus hernia **BLACK Traffic Light**
- e. **Budesonide multimatrix (Cortiment®)** – Currently RED on ELMMB for the induction of remission in adults with mild to moderate active ulcerative colitis where 5-ASA treatment is not sufficient. **AMBER Traffic Light**
- f. **Estradiol / micronized progesterone (Bijuve®)** – Continuous hormone replacement therapy **GREEN restricted Traffic Light**
- g. **Therabite®** - 2<sup>nd</sup> line option for patients with trismus/mandibular hypomobility secondary to radiotherapy, surgery or trauma who are still experiencing problems despite regular use of passive jaw stretching exercises. **RED Traffic Light**
- h. **Trifarotene cream (Aklief® 50 microgram/g)** For the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. **GREEN Traffic Light**
- i. **Hydrocortisone sodium phosphate eye drops (Softacort®)** For Treatment of mild non-infectious allergic or inflammatory conjunctival diseases. **RED Traffic Light**
- j. **Avanafil (Spedra®)** For the treatment of erectile dysfunction in adult men who are unable to tolerate sildenafil and tadalafil. **GREEN restricted Traffic Light**



- k. Fluorouracil 5% cream** (Efudix®) For the topical treatment of superficial pre-malignant skin lesions. **GREEN Traffic Light**
- l. Adalimumab biosimilar** – (Hyrimoz®) cost saving alternative to Amgevita and Humira for new patients. **RED Traffic Light**
- m. Betnesol drops** - (betamethasone 0.1%) As alternative to Flixonase nasules (limited availability until December 2023) for the regular treatment of nasal polyps and associated symptoms of nasal obstruction. **GREEN Traffic Light**
- n. Naltrexone + Crystacide** – Requested by Will price for a specific adult patient with rare dermatosis (Hailey Hailey disease - HHD), The naltrexone is a lower dose formulation [special product] and is similar in cost to the formulary preparation. Members agreed to add to formulary as red traffic light, remaining under specialist review. **RED Traffic Light**

**Resolved:** ELMMB formulary will be updated accordingly

**2023/113: LSCMMG Consultations – September 2023 [deadline 4<sup>th</sup> September 2023]**

It was noted and fed back to LSCMMG that there had been a poor response to the consultations due to the consultations being released during the August holiday period.

**ELMMB nefopam position statement:** based on the evidence ELMMB does not support the prescribing of nefopam is currently assigned as Black traffic light in the position statement. A summary of the evidence/comments included:

- don't initiate nefopam for acute or chronic pain.
- do not continue nefopam post discharge following secondary care acute initiation.
- review existing patients – assess benefits versus adverse effects and consider stopping.
- withdraw slowly over 1-2 weeks following chronic use.

**ACTION:** LR to send all the comments to LSCMMG

**Cenobamate** Currently red traffic light as per NICE TA753 for focal onset seizures in epilepsy. RAG review: proposed switch from red to amber0

**Ibandronic Acid 50 mg tablets:** for the adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence – proposed amber 1.

**Flupentixol RAG rating:** currently Amber traffic light on ELMMB, proposed green.

**Brimonidine Tartrate (Mirvaso) 3mg/g Gel:** Currently Black traffic Light on ELMMB, proposed green restricted.

**COPD guideline:** The guidelines are considered too long and a desktop/shortened version would be more helpful for practitioners.

**Melatonin guideline(children):** this is a re-consultation with previous comments and CSU response to comments. It was noted that the comments submitted from paediatric consultants had not been acknowledged at the LSCMMG meeting.



All documents have been circulated to appropriate directorate.

**For Action:** Comments to be sent to LSCMMG.

### **LSCMMG Recommendations – October 2023 [deadline 9<sup>th</sup> October 2023]**

**Tacrolimus position statement:** ELHT has a new contract to use Dailiport MR capsules. Position Statement clarifies the prescribing of oral tacrolimus recommending that Dailiport are only recommended for patients newly prescribed modified release tacrolimus for transplant rejection. They are not bioequivalent to and do not replace Adoport immediate release capsules.

**For Action:** Comments to be sent to LSCMMG.

### **2023/114 LSCMMG Recommendations – June to August 2023**

#### **June 2023**

**Levetiracetam (Keppra®) prescribing:** bioequivalence and antiepileptic drugs - position statement and SOP. New document.

**Antihistamine position statement** (interim LSCMMG guidance); supports NHSE guidance on conditions for which over the counter items should not be routinely prescribed.

**Gluten free products position statement** (interim LSCMMG guidance): Prescribing of GF products for use in coeliac disease or other gluten intolerances not recommended.

**Lipid Management Pathway for Primary Prevention of Cardiovascular Disease (CVD):** new guideline.

**Primary Care Management of Menopause** - guideline and product relative cost list: new guideline.

#### **July 2023**

**Nutritional Supplements Post Bariatric Surgery:** updated with improved clarity of table indicating which items should be prescribed or purchased. Updated document

**Algorithm For Antihyperglycaemic Therapy in Adults with Type 2 Diabetes:** updated to include updated information from NICE NG28, renal appendix updated and choice of GLP-1s amended to account for supply issues.

**Lipid Management Guidance for Secondary Prevention of CVD:** new guidance

**Resolved:** items acknowledged by ELMMB. Website will be updated accordingly.

### **2023/115 Other Items**

#### **Standard Operating Procedure for Carer Administration of Subcutaneous Medication in Palliative Care [CIC]**

Presented by Dr Anna Macpherson. The SOP has been developed to allow a very small number of carers/relatives to give sub-cutaneous medicines in the last days of life. This will be dependent on the situation with the carer/relative receiving being trained by the district nurse (DN) to give a specific dose of drug. The dose, timing will be set by the district nurse and when given by the carer/relative they will contact the DN to confirm it has been



given. This will trigger the DN to follow up. There is a set number of times a dose can be administered.

The administration of doses will be recorded on the same form used by DNs.

Full training will be given to the carer/relative by the DN and they will only be permitted to administer medication if they are considered competent. JV asked for assurances that the intention to use this SOP would only be on request from a carer/relative and not 'promoted' by the district nursing team.

The SOP was approved for use with the caveat that an audit to monitor usage, incidents and numbers will be fed back to ELMMB and/or the Drug Safety committee in September 2024.

**Resolved:** Approved for use

#### 2023/116 Other Items

**ELHT Natpar guideline v1:** guideline not applicable as medicine withdrawn.

**Resolved:** Item acknowledged by ELMMB

#### 2023/117 Other Items

**NEW DRAFT- ELHT Eczema Guideline V3 2023:** Will Price, dermatology specialist pharmacist, presented the re-formatted document. Specific emollients have been removed and quantities to use has been added. It was agreed that the document be shared with LSCMMG to consider adoption.

**Resolved:** Updated document to be uploaded to ELMMB.

#### 2023/118 Other Items

##### **L&SC formulary - East Lancs Cardiovascular discrepancies**

Metolazone: **Amber** [currently Red]

Labetalol (oral): **Green** [currently Amber]

Furosemide 500mg tabs: **Amber** [currently Amber]

Propafenone: **Amber** [Not on ELMMB]

**Resolved:** Final ELMMB Rag decisions to be sent to LSCMMG

#### 2023/119 Other Items

##### **a. L&SC formulary - East Lancs Gastro Anomalies**

Naldemedine: **Green** [currently Red]

Glyceryl trinitrate 0.4% ointment: **Green** [currently Amber]

Rabeprazole: **Black** [currently Green]

Pantoprazole injection: **Red**, restricted to ICU use only. [currently Red]

**Resolved:** Final ELMMB Rag decisions to be sent to LSCMMG

##### **b. L&SC formulary - East Lancs Gastro Omissions**

Scheriproct (cinchocaine with prednisolone): **Green** [Not on ELMMB]

Cimetidine: **Amber** [Not on ELMMB]

**Resolved:** Final ELMMB Rag decisions to be sent to LSCMMG



### 2023/120 NICE Guidance: July – August 2023

**NG83** Oesophago-gastric cancer: assessment and management in adults. Updated 4<sup>th</sup> July 2023

**NG122** Lung cancer: diagnosis and management. Updated 26<sup>th</sup> July 2023

**CG189** Obesity: identification, assessment, and management. Updated 26<sup>th</sup> July 2023

**NG158** Venous thromboembolic diseases: diagnosis, management, and thrombophilia testing. Updated 2<sup>nd</sup> August 2023

**NG126** Ectopic pregnancy and miscarriage: diagnosis and initial management. Updated 23<sup>rd</sup> August 2023

**NG233** Otitis media with effusion in under 12s. Updated 30<sup>th</sup> August 2023

### 2023/121 NICE Recommendations: July – August 2023

**Rimegepant** for preventing migraine is recommended as an option by **NICE TA906**.

**AMBER Traffic Light**

**Olaparib** for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy is recommended as an option by **NICE TA908**.

**RED Traffic Light**

**Lorlatinib** for untreated ALK-positive advanced non-small-cell lung cancer is not recommended as an option by **NICE TA909**.

**BLACK Traffic Light**

**Semaglutide** for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) is not recommended as an option by **NICE TA910**.

**BLACK Traffic Light**

**Selpercatinib** for untreated RET fusion-positive advanced non-small-cell lung cancer is recommended as an option by **NICE TA911**

**RED Traffic Light**

**Cipaglucosidase** alfa with miglustat for treating late-onset Pompe disease is recommended as an option by **NICE TA912**.

**RED Traffic Light**

**Resolved:** ELMMB website will be updated accordingly

### 2023/122 NICE Highly Specialised Technologies: July – August 2023

**HST27 Afamelanotide** for treating erythropoietic protoporphyria. Updated 26<sup>th</sup> July 2023

**Resolved:** Item acknowledged by ELMMB

### 2023/123 EAMS (Early access to medicines scheme): July – August 2023

**Glofitamab** in the treatment of diffuse large B-cell lymphoma (DLBCL)

**Dostarlimab** in the treatment of endometrial cancer

**Resolved:** Items acknowledged by ELMMB

### Standing Items:

**2023/124 For Action/Information:** Lancashire & South Cumbria Medicines Management Group (LSCMMG)

a. LSCMMG-minutes Draft 13.07.2023





**Resolved:** Draft minutes acknowledged

**2023/125 For Action/Information:** Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Minutes and open action tracker from 20<sup>th</sup> July 2023

Next meeting 28<sup>th</sup> September 2023.

**Resolved:** Minutes and open action tracker acknowledged

**2023/126 For Action/Information:** Antimicrobial Stewardship Committee (ASC)

13<sup>th</sup> June 2023 minutes.

It was recommended that ciprofloxacin ear drops be removed from formulary (currently RED traffic Light) and assigned a **BLACK traffic light**.

**Resolved:** Minutes acknowledged, ciprofloxacin ear drops to be removed from formulary and assigned a BLACK traffic Light

**2023/127 Any Other Business**

**a. Medicine Supply Notification - Permethrin 5% w/w cream**

There are still supply issues with permethrin 5% cream and a Medicine Supply Notification was issued in support by the DHSC.

**b. NHS L&SC Scabies Operational Clinical Pathway v 1.12.2\_DRAFT**

There have been numerous outbreaks, some repeated, in care home and closed settings. To support clinicians, care home managers and closed settings to manage the outbreaks effectively a clinical pathway has been developed in collaboration with UKHSA, ICB and ELHT colleagues.

The pathway offers clinical advice, contact details and support for both clinicians and managers e.g., treatment failure, treatment of Norwegian scabies, follow-up of contacts.

**Resolved:** The pathway was approved by ELMMB and will be circulated accordingly

**2023/128 Any Other Business**

**Use of Semaglutide in overweight/obese patients with NASH:** JE, BH asked if there were any updates to the availability of Semaglutide (Wegovy®) in ELHT.

It was reported that there are still ongoing discussions as to how this can be managed across Lancashire and South Cumbria Commissioners to develop a pathway and set the criteria to access the service.

There is a pilot in development which will take the form of a digital platform to provide an option to accessing weight management support to those people who live in an area with no specialist weight management services or for those who are on a waiting list and are happy to be treated safely outside a hospital setting.

**ACTION:** JE to feedback to gastro team Item will be revisited APRIL 24

**2023/129 Any Other Business New Product Request**

**Ibuprofen (200mg and 400mg) solution for infusion:** Requested by Mr M tattersall, clinical pharmacist for anaesthetics and critical care as an alternative option management of peri-operative pain. This will replace the use of parecoxib IV. Ibuprofen solution for infusion is a cheaper option, with no preparation required, meaning less use of consumables. The dosing is the same as oral preparation and can be used in patients allergic to oral ibuprofen, avoiding the use of an opiate.



**Resolved:** Approved for use.

**RED Traffic Light**

**DATE OF NEXT MEETING – Wednesday 18<sup>th</sup> October 2023 12.30pm via ‘Microsoft Teams’**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 27<sup>th</sup> September 2023**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
2023/128	Use of Semaglutide in overweight/obese patients with NASH: update to pathway/commissioning situation to be provided as and when there is an update.	All	April 24